Skip to main content

Amphastar Pharmaceuticals Inc. Value Stock - Dividend - Research Selection

Amphastar pharmaceutical

ISIN: US03209R1032 , WKN: A11664

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Amphastar Pharmaceuticals (NASDAQ:AMPH) Stands Out as a Quality Investing Candidate

2026-08-15
Amphastar (AMPH) passes quality screen with 17.2% ROIC, 104% profit quality, and cheap valuation, but revenue growth lags.

Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20

2026-08-07
Piper Sandler analyst David Amsellem maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target from $21 to $20.

Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $20

2026-08-07
Wells Fargo analyst Benjamin Burnett maintains Amphastar Pharma (NASDAQ:AMPH) with a Equal-Weight and raises the price target from $19 to $20.

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript

2026-08-07
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call August 6, 2026 5:00 PM EDTCompany ParticipantsDan Dischner - Senior Vice President of Human...

Amphastar Pharmaceuticals (NASDAQ:AMPH) Beats Q2 Earnings Estimates, Shares Rise After Hours

2026-08-06
Amphastar Q2 EPS $0.91 beats $0.63 est., revenue $183.9M inline, shares +2.7% AH.

Amphastar Pharma Q2 Adj. EPS $0.91 Beats $0.62 Estimate, Sales $183.903M Beat $182.055M Estimate

2026-08-06
Amphastar Pharma (NASDAQ:AMPH) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.62 by 46.77 percent. This is a 7.06 percent increase over earnings of $0.85 per share from

Two Years to Build or Pay 200% — Which US Pharma Stocks Win?

2026-07-24
Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.

Viatris Announced That Japan's Ministry Of Health, Labour And Welfare Has Approved Effexor Sr 37.5 Mg / 75 Mg Capsules (Venlafaxine Hydrochloride), A Serotonin-noradrenaline Reuptake Inhibitor, For The Treatment Of Adults With Generalized Anxiety Disorder

2026-07-22

Amphastar Pharmaceuticals (NASDAQ:AMPH) Screens as a High-Quality Stock with Deep Value Appeal

2026-07-18
Amphastar Pharmaceuticals (AMPH) is a quality investing pick with strong profitability, 15.12% ROIC, low debt, and a P/E of 6.74, offering a rare blend of value and durable cash flows.

Amphastar Pharmaceuticals Unit International Medication Systems Receives FDA Warning Letter Regarding Violations Of Current Good Manufacturing Practice At IMS's Drug Manufacturing Facility In California

2026-07-08
On July 2, 2026, International Medication Systems, Limited ("IMS"), a subsidiary of the Company, received a warning letter (the "Warning Letter") from the FDA relating to IMS's drug manufacturing